Share This Page
Suppliers and packagers for testopel
✉ Email this page to a colleague
testopel
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | TESTOPEL | testosterone | PELLET;IMPLANTATION | 080911 | ANDA | Endo USA, Inc. | 66887-004-10 | 10 AMPULE in 1 BOX (66887-004-10) / 1 PELLET in 1 AMPULE (66887-004-01) | 2014-10-31 |
| Endo Operations | TESTOPEL | testosterone | PELLET;IMPLANTATION | 080911 | ANDA | Endo USA, Inc. | 66887-004-20 | 100 AMPULE in 1 BOX (66887-004-20) / 1 PELLET in 1 AMPULE (66887-004-01) | 2014-10-31 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ecutive summary Testopel (testosterone pellet) is supplied through a limited manufacturing and distribution ecosystem tied to the brand’s FDA-approved supply chain. The active ingredient and pellet manufacturing are concentrated in the brand’s control, while external suppliers typically support secondary inputs (sterile packaging components, implant applicators, and distribution). Publicly determinable supplier lists at the level of contract-manufactured drug product and site-specific raw-material sources are not consistently disclosed in FDA labeling, Orange Book entries, or routine public filings.
Testopel suppliers: Who manufactures the testosterone pellets and implant components?
Answer: Testopel is manufactured and distributed by the brand authorization holder’s supply chain; external “supplier” visibility is limited to what appears in FDA labeling and public regulatory records. The drug-product manufacturing supplier is not reliably enumerated as named contract manufacturers in widely indexed sources.
What does the US label identify?
Testopel’s US prescribing information identifies the manufacturer/distributor and provides handling and administration details, but does not always enumerate upstream raw-material suppliers or contract manufacturing sites in a way that supports a complete supplier map.
Implant system: Are suppliers limited to the pellet drug product?
Testopel systems typically include:
- Testosterone pellet drug product (the implant)
- Sterile surgical/implant components and applicator hardware (depending on packaging configuration)
These can involve different suppliers (drug substance, drug product filling and finishing, sterile packaging, and implant instruments), but only certain parties are named in public-facing sources.
What patents protect Testopel pellet manufacturing, applicators, and formulations?
Answer: Patent protection for testosterone pellet implants spans formulation/manufacturing, pellet characteristics, insertion systems, and treatment methods. The key risk for supplier entry is that contract supply must avoid infringing brand-specific process and device claims and must meet FDA comparability/CMC expectations.
Patent estate drivers suppliers must navigate
Supplier viability is usually constrained by:
- Pellet composition and manufacturing process claims
- Sterility assurance, pellet dimensions/handling properties, and release characteristics
- Applicator or insertion method claims
- Method-of-use claims tied to testosterone replacement regimens
How patent scope affects contract manufacturing
A contract manufacturer may be able to supply pellet inputs only if:
- The process does not infringe protected manufacturing steps
- The design of pellets and insertion workflow falls outside protected ranges
- The sterile packaging and device interfaces are compatible with regulatory submissions
What is the Orange Book status of Testopel?
Answer: Testopel is an FDA-approved drug product with Orange Book listings tied to patents and exclusivity periods. The Orange Book entry is the authoritative index for patent numbers connected to the marketed product, and it drives Paragraph IV and licensing strategies for generic or authorized replacements.
What Orange Book data usually implies for supplier sourcing
Orange Book listings typically support:
- Identification of listed patents (drug product, formulation, method of use)
- Identification of the NDA sponsor/holder controlling the reference product supply chain
- A view into the likely scope of protected CMC and formulation steps suppliers would need to design around
When does Testopel lose exclusivity or patent protection?
Answer: Exclusivity and patent expiration timelines determine whether alternate manufacturers can supply a generic or authorized product without licensing or infringement risk. Supplier switching in practice usually follows (1) legal freedom-to-operate and (2) CMC/regulatory clearance for the specific dosage form and implant device workflow.
What timing affects supplier decisions
- Patent expiration of key drug-product/formulation patents
- Any paediatric exclusivity extensions (if applicable)
- Market exclusivity periods that block generic approval pathways tied to the reference product
Which companies are challenging Testopel with generics or Paragraph IV ANDAs?
Answer: Generic competition for testosterone implant pellets depends on the feasibility of demonstrating bioequivalence and pellet-specific performance. Public Paragraph IV activity is not uniformly visible at a level that enables a complete, site-specific supplier challenge map from standard indexed sources.
Why “pellet” generics are harder than many other dosage forms
- Implant-specific release kinetics
- Sterile manufacturing requirements
- Device-applicator workflow and administration performance
What generic entry risks exist for Testopel pellet implants?
Answer: Generic entry risks concentrate in CMC comparability, pellet performance characteristics, sterile packaging, and patent landscape noninfringement.
Typical risk categories
- Pellet size/weight and release profile alignment
- Sterility assurance validation for implant-grade materials
- Device compatibility and administration workflow
- Patent noninfringement or successful settlement strategies
How does Testopel compare with other testosterone pellet brands on supplier and IP barriers?
Answer: Comparative IP and supplier structure is driven by each brand’s Orange Book patent listings and CMC package differences. Even when active ingredient is testosterone, pellet formulation, manufacturing method, and insertion system design can differ and change freedom-to-operate outcomes.
Supplier switching constraints across products
- Device/applicator integration
- Pellet manufacturing method dependencies
- Sterile packaging specification differences
What formulation patents protect testosterone pellet implants like Testopel?
Answer: Testosterone pellet implant formulation patents typically protect:
- Pellet composition and excipient systems
- Pellet manufacturing method steps
- Release characteristics achieved by pellet geometry and processing parameters
What this means for suppliers
A supplier cannot treat pellet manufacturing as commodity production. Process windows, particle/matrix properties, pellet geometry controls, and release tuning can fall within patent scopes.
How does FDA labeling govern suppliers for Testopel?
Answer: FDA labeling and approval documents establish:
- Approved dosage form and strength
- Administration method and patient selection constraints
- Manufacturer identity (at least at the NDA sponsor or label manufacturer level)
Where suppliers are typically disclosed
- Label “Manufactured for / Distributed by” lines
- NDA review documents (not always publicly indexed at site granularity)
- Biopharm and CMC summaries included in FDA disclosure releases (limited in many cases)
What commercial impact do supply constraints have for Testopel?
Answer: Implant drugs are sensitive to:
- Sterile manufacturing capacity
- Pellet batch scheduling and shelf-life constraints
- Applicator/device packaging availability
- Distribution lead times for sterile kits
Supplier risk levers
- Single-site dependence
- Long lead-time components for sterile packaging
- Device/applicator component availability for implantation workflow
Key Takeaways
- Testopel supplier identification at the level of specific upstream raw-material or contract-manufacturing sites is not consistently available in the same way as for many oral solid-dose generics; public visibility is largely limited to label-level manufacturer/distributor references and Orange Book patent-linked control points.
- The practical supplier landscape is constrained by pellet-specific CMC, sterility, and insertion workflow requirements, plus a patent estate that typically spans pellet manufacturing and device-administration aspects.
- Freedom-to-operate for alternate supply requires aligning CMC execution with both FDA requirements and the active patent landscape indexed in the Orange Book.
FAQs
-
Are testosterone pellet suppliers allowed to use the same manufacturing process as Testopel?
Only if the process does not infringe listed patents and the FDA CMC package supports approved comparability for pellet performance and sterility. -
Does Testopel use a contract manufacturer for sterile packaging and implant kits?
Public disclosures vary; label and regulatory documents typically identify the NDA sponsor/manufacturer but not always each kit component supplier. -
Can a generic testosterone pellet replace Testopel without a licensed pellet formulation?
Only if the generic avoids infringement of formulation and process patents and satisfies FDA bioequivalence/quality expectations for pellets and implant delivery. -
Do patent expirations automatically enable new suppliers for Testopel?
No. New suppliers still need FDA regulatory clearance for the specific product and must satisfy remaining IP constraints from nonexpired patents and potential process/device claims. -
Which regulatory documents most directly reveal Testopel manufacturing details?
FDA labeling and Orange Book listings are the most consistently indexed public sources; deeper manufacturing detail sits in NDA review materials and CMC disclosures, which may not be fully site-disclosed publicly.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Testopel entries). U.S. Food and Drug Administration.
- FDA. Testopel prescribing information (label/manufacturer and distribution statements). U.S. Food and Drug Administration.
More… ↓
